Our aim: To provide the scientific/medical community and the pharmaceutical companies with our expertise on the evaluation of the impact of cancer and its treatment on patients’ cognitive functions.

A major challenge: the number of patients in remission after cancer is constantly increasing. Furthermore, there is an increasing number of targeted therapies for personalized cancer therapy. Questions about the impact of these new molecules on patient care are being raised, particularly concerning the management of potential side effects.

Cognitive troubles may occur during chemotherapy and/or targeted treatment, with an impact on patient quality of life, autonomy and adherence to treatments. Accordingly, the onset of cognitive disorders is a frequent patient complaint.

These disorders result in difficulty remembering, concentrating, and thinking, with important consequences for daily quality of life. Some populations, such as elderly patients, seam more heavily affected than others by these difficulties due to possible pre-existing frailty. Thus, the study of these identified groups at risk is particularly important.

The identification and evaluation of these disorders are not yet optimally integrated into patient care, and the underlying mechanisms are still largely unknown.

Our unique multidisciplinary platform allows us to explore this recently identified problem. We propose four services :

  • Clinical Expertise
  • Neuropsychological Expertise
  • Preclinical and Biomarker Expertise
  • Biostatistical Expertise

The on-line publishing of this website will make the convergence of cross expertises possible for the consideration, the understanding and the improvement of cognitive disorders induced by cancer and its treatments.

Florence Joly, MD-PhD, Oncologist
Plateforme Cancer et Cognition Manager

UTLC video conference : forget the cancer, not the rest!
When cancer and its treatments fill your mind with fog

Cancer patients can exhibit cognitive disorders such as confusion, visual and spatial memory disorders, mental flexibility or psychomotor slowing. These disorders are described in the literature under the term “chemofog ” in reference to London’s thick fog. See the video, lenght 1 hour